Sun Pharmaceutical Industries Ltd said it was allowed to launch a generic version of Novartis’ leukemia drug Gleevec in the United States on Feb. 1, 2016, under a settlement agreement between the two companies.
The other terms of the agreement are confidential, Sun Pharma said in a statement on Thursday.
Sun Pharma’s subsidiary holds a tentative approval from the U.S Food and Drug Administration for a generic version of Gleevec. As per IMS data, Gleevec had annual sales of about $2 billion in the United States, Sun said.
What Is Pm’s Mann Ki Baat On Racist Comments-cpi(m) To Nnis
Prayers Held In Kashmir For Mercy Of Rain Gods (nnis Special)
Sisodia - Shame On Bjp As Safaikarmacharis Suffer
Bharat Singh Murder: Police Looking Into Matter, Says Bassi
Vintage Design: The Montblanc Fountain Pen
The Holiday Professionals - A Chef In Portugal